# Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

> **NCT03406715** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 14 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Lung Cancer
- Relapsed Small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **BIOLOGICAL:** Dendritic Cell based p53 Vaccine

## Key facts

- **NCT ID:** NCT03406715
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-15
- **Primary completion:** 2022-03-23
- **Final completion:** 2022-05-16
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Sponsor closed study
- **Last updated:** 2023-03-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03406715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03406715, "Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03406715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*